The Supreme Court of the United States has agreed to resolve a pivotal question concerning induced patent infringement liability: whether advertising a product merely as a “generic” version of a patented brand-name drug, without specifying approved uses, can give rise to liability for induced infringement.
This issue arises in the context of Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (Docket No. 24-889), a case involving generic drug manufacturers’ potential liability for induced patent infringement. The Court granted certiorari on two key questions, the first of which pertains specifically to the pharmaceutical industry.
Under the Hatch-Waxman Act, generic drugs may receive FDA approval for certain non-patented uses of a brand-name drug, resulting in so-called “skinny labels” that carve out patented uses from the generic’s approved indications. While generics can be prescribed off-label, including for patented uses, the question is whether advertising a generic drug broadly as a “generic” for the brand-name drug—without limiting marketing to the skinny label—can expose the generic manufacturer to induced infringement claims.
The second question presented concerns the pleading standards for induced patent infringement generally. It asks whether a patent owner’s claim for induced infringement is sufficiently pleaded absent allegations that the defendant instructed, encouraged, or referenced the patented use.
Induced infringement under 35 U.S.C. § 271(b) requires that a third party directly infringe a patent following the defendant’s inducement, which must be done with knowledge that the induced acts constitute infringement. Courts have held that inducement involves recommending, encouraging, or promoting infringing uses, as articulated in Takeda Pharmaceuticals U.S.A., Inc. v. West-Ward Pharm. Corp., 785 F.3d 625, 631 (Fed. Cir. 2015).
The Federal Circuit previously ruled that Hikma’s advertising could give rise to liability for induced infringement. Amarin alleged that Hikma’s marketing materials described its drug as “generic Vascepa®” without limiting the promotion to the skinny label’s approved uses. Hikma’s materials also referenced sales and usage data for brand-name Vascepa® broadly, not confined to the approved indications for Hikma’s generic.
The Federal Circuit found these allegations sufficient to survive a motion to dismiss, reasoning that the impact of Hikma’s marketing on third parties who might infringe by prescribing the generic for patented uses presented factual questions inappropriate for resolution at the pleading stage. The court held that, considering the totality of circumstances, Amarin plausibly alleged that Hikma’s messaging recommended or encouraged infringing uses to physicians and others.
The Supreme Court’s forthcoming decision will weigh complex factors, including First Amendment protections for commercial speech, patent holders’ rights, and the Hatch-Waxman Act’s framework balancing generic drug market entry with patent exclusivity.
Beyond pharmaceuticals, the ruling is expected to influence induced infringement claims across various patent fields, including software and automotive parts. Because the case addresses pleading standards at the motion to dismiss stage, it may also affect civil litigation procedures more broadly.
Notably, the Supreme Court had declined to review this issue in 2022 in GlaxoSmithKline v. Teva, despite urging from the executive branch. This time, the Court’s grant of certiorari—also supported by executive branch recommendations to reverse the Federal Circuit—signals a potential shift toward limiting induced infringement liability in this context.
Oral argument has not yet been scheduled but is anticipated in the spring, with a decision expected by the end of June. Intellectual property practitioners and stakeholders in pharmaceutical patent litigation will closely monitor the outcome for its wide-ranging implications.
For further guidance, parties are advised to consult with experienced intellectual property counsel.
Supreme Court to Define Limits of Induced Patent Infringement Liability in Generic Drug Advertising The U.S. Supreme Court has granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. to clarify when advertising a generic drug as a ‘generic’ for a patented brand-name drug can lead to liability for i... Read the full IIPLA article: https://iipla.org/news/supreme-court-to-define-limits-of-induced-patent-infringement-liability-in-generic-drug-advertising